{"id":2844,"date":"2018-03-21T10:40:05","date_gmt":"2018-03-21T14:40:05","guid":{"rendered":"http:\/\/www.drugpatentwatch.com\/blog\/?p=2844"},"modified":"2026-10-23T22:33:45","modified_gmt":"2026-10-24T02:33:45","slug":"obstacles-opportunities-chinese-pharmaceutical-innovation","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/obstacles-opportunities-chinese-pharmaceutical-innovation\/","title":{"rendered":"China Pharma IP: The Patent Rules Behind a $135.7B Deal Year"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Chinese drug developers signed 157 out-licensing deals in 2025. Total deal value was $135.7 billion, up from $51.9 billion across 94 deals in 2024. Upfront payments were $7.0 billion. These are PharmCube figures published by DIA Global Forum. [1]<\/a><\/p>\n\n\n\n

The deal numbers get the headlines. The IP rules decide who keeps the value. China added patent term extension and a patent linkage system in 2021. [5]<\/a> [7]<\/a> It added a regulatory data protection regime on May 15, 2026. [3]<\/a> This article explains how those rules work, what the deal data shows, and which US actions could change the picture. The data is current as of October 23, 2026.<\/p>\n\n\n\n

The Short Answer<\/strong><\/h2>\n\n\n\n

China now has the main IP tools that a Western innovator expects: extended patent terms, data protection, a pre-approval patent dispute process, and a reimbursement list for new drugs. Each tool is recent. The data protection regime is five months old. [3]<\/a> [21]<\/a><\/p>\n\n\n\n

The large licensing deals of 2025 and 2026 sit on top of this system. Pfizer, GSK and AstraZeneca each paid at least $500 million upfront to a Chinese licensor. In each deal, the buyer’s license excluded China. [14]<\/a> [15]<\/a> [16]<\/a><\/p>\n\n\n\n

The main obstacles are outside the patent system. They are the BIOSECURE Act and FDA scrutiny of data from Chinese trial sites. [9]<\/a> [12]<\/a> A draft US order on licensing was also reported in September 2025. [13]<\/a><\/p>\n\n\n\n

The Findings That Matter: What the Data Shows<\/strong><\/h2>\n\n\n\n

Each finding below can be quoted alone. Items marked “Analysis” are our own calculations from the cited inputs. They are not figures reported by the cited source.<\/p>\n\n\n\n

    \n
  1. China out-licensing value rose from $51.9 billion in 2024 to $135.7 billion in 2025. Deal count rose from 94 to 157. Upfront payments were $7.0 billion. [1]<\/a><\/li>\n\n\n\n
  2. Analysis: Upfront cash was 5.2% of 2025 headline deal value ($7.0 billion divided by $135.7 billion). Average headline value per deal rose from about $552 million to about $864 million.<\/li>\n\n\n\n
  3. NMPA approved 120 new drugs in 2025 (not counting traditional Chinese medicines). Of these, 63 came from domestic developers and 57 were imported. [2]<\/a><\/li>\n\n\n\n
  4. Analysis: 61 of the 120 approvals, or 50.8%, were the first approval anywhere in the world. [2]<\/a><\/li>\n\n\n\n
  5. China’s regulatory data protection measures took effect on May 15, 2026. They give six years to innovative drugs, four years to improved drugs, and three years to certain first approved generics. [3]<\/a> [4]<\/a><\/li>\n\n\n\n
  6. China’s Patent Law allows a patent term extension of up to five years, with total patent life after approval capped at 14 years. [5]<\/a><\/li>\n\n\n\n
  7. As of November 14, 2025, China’s patent office (CNIPA) had issued 183 administrative decisions in drug patent linkage cases. Of these, 98 were withdrawn. [8]<\/a><\/li>\n\n\n\n
  8. Analysis: Among the 71 CNIPA decisions that reached a scope finding, 37 (52.1%) found the generic inside the patent scope and 34 (47.9%) found it outside. [8]<\/a><\/li>\n\n\n\n
  9. The BIOSECURE Act became law on December 18, 2025. The Office of Management and Budget (OMB) must publish its list of companies of concern no later than one year after that date. [9]<\/a><\/li>\n\n\n\n
  10. In all four licensing deals we checked against company releases (Pfizer and 3SBio, GSK and Hengrui, AstraZeneca and CSPC, Summit and Akeso), the Western licensee’s territory excluded China. [14]<\/a> [15]<\/a> [16]<\/a> [18]<\/a><\/li>\n<\/ol>\n\n\n\n

    How We Built This Analysis (Methodology)<\/strong><\/h2>\n\n\n\n

    What data did we analyze, and over what period?<\/strong><\/h3>\n\n\n\n

    We used public sources dated from August 2015 to October 2026. Most inputs date from 2025 and 2026. We took deal terms from company press releases where they exist. We took regulatory rules from law-firm analyses of the NMPA measures and from NMPA’s own announcement. We took patent linkage statistics from a published case overview that states a cutoff date of November 14, 2025. [8]<\/a><\/p>\n\n\n\n

    How did we select and calculate records?<\/strong><\/h3>\n\n\n\n

    We included a deal only if a company release or a named industry tracker gave its upfront and total values. We did not merge datasets. Where trackers disagree, we show both figures and name the source. We did not remove duplicates across trackers because we did not combine them.<\/p>\n\n\n\n

    All percentages marked “Analysis” use one formula: the part divided by the whole, rounded to one decimal place. For deals, “headline value” means upfront payment plus the quantified milestone payments stated by the source. We left out equity investments and unquantified royalties.<\/p>\n\n\n\n

    What are the limits of this analysis?<\/strong><\/h3>\n\n\n\n

    Four limits apply. First, deal totals come from third-party trackers, and trackers use different definitions. Second, headline values include payments that may never occur. Third, we did not search Chinese patent registers drug by drug, so this article does not list patent expiry dates for individual drugs. Fourth, the linkage statistics come from one secondary source, not from CNIPA’s own database.<\/p>\n\n\n\n

    What Is China’s Pharmaceutical Innovation Ecosystem?<\/strong><\/h2>\n\n\n\n

    Definitions used in this article<\/strong><\/h3>\n\n\n\n

    Patent term extension (PTE) is extra patent life granted to make up for time lost during regulatory review. Regulatory data protection (RDP) bars the regulator from approving a follow-on product that relies on the originator’s data. Patent linkage ties generic approval to the resolution of patent disputes. Out-licensing means a company grants rights in its asset to another company, usually for a defined territory.<\/p>\n\n\n\n

    A “biobuck” is a milestone counted in headline deal value that is paid only if a defined event occurs. DrugPatentWatch describes this as industry shorthand, not a legal term. [17]<\/a><\/p>\n\n\n\n

    An original framework: the five-layer IP stack<\/strong><\/h3>\n\n\n\n

    This is our own framework, not an industry standard. We use it to sort China’s rules by what each one does for an asset holder.<\/p>\n\n\n\n

    Layer<\/th>What it controls<\/th>China mechanism<\/th>Source<\/th><\/tr><\/thead>
    1. Patent term<\/td>How long the patent lasts<\/td>PTE up to 5 years; 14-year cap after approval<\/td>[5]<\/a><\/td><\/tr>
    2. Data exclusivity<\/td>How long followers must wait<\/td>6, 4 or 3 years by category (2026 measures)<\/td>[3]<\/a> [4]<\/a><\/td><\/tr>
    3. Enforcement<\/td>When patent disputes get resolved<\/td>Patent linkage; 9-month stay for chemical generics<\/td>[7]<\/a> [8]<\/a><\/td><\/tr>
    4. Territory<\/td>Who holds rights where<\/td>Licenses that exclude China<\/td>[14]<\/a> [15]<\/a> [16]<\/a><\/td><\/tr>
    5. Access<\/td>Whether the product gets paid for and moved across borders<\/td>NRDL; BIOSECURE; FDA data review<\/td>[21]<\/a> [9]<\/a> [12]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    How Did China Get Here? A Timeline From 2015 to 2026<\/strong><\/h2>\n\n\n\n

    2015 to 2017: approval reform and ICH membership<\/strong><\/h3>\n\n\n\n

    On August 18, 2015, China’s State Council issued Opinions (Guo Fa [2015] No. 44) on reform of drug and device approval. [25]<\/a> The Opinions started a market authorization holder pilot, so research institutions and not only manufacturers could apply for approval. [25]<\/a> They extended priority review to innovative drugs and allowed qualified multicenter trial data to support applications. [25]<\/a><\/p>\n\n\n\n

    In 2017, Japan’s health ministry reported that the ICH meeting in Montreal, held from May 27 to June 1, approved China’s drug regulator (then CFDA) as a new regulatory member. [26]<\/a><\/p>\n\n\n\n

    2021: Patent Law amendment and linkage go live<\/strong><\/h3>\n\n\n\n

    The National People’s Congress Standing Committee passed the amended Patent Law on October 17, 2020. It took effect on June 1, 2021. [6]<\/a> Article 76 created the linkage system. [6]<\/a> The implementing measures came into force on July 4, 2021, the same day the patent platform became fully operational. [7]<\/a><\/p>\n\n\n\n

    2025 to 2026: deal growth, new exclusivity, and US response<\/strong><\/h3>\n\n\n\n

    The pace of change rose after 2024. The table lists the dated events we verified.<\/p>\n\n\n\n

    Verified timeline table<\/strong><\/h4>\n\n\n\n
    Date<\/th>Event<\/th>Status<\/th>Source<\/th><\/tr><\/thead>
    Aug 18, 2015<\/td>State Council Opinions on drug and device approval reform<\/td>Confirmed<\/td>[25]<\/a><\/td><\/tr>
    May 27 to Jun 1, 2017<\/td>ICH approves CFDA as regulatory member<\/td>Confirmed<\/td>[26]<\/a><\/td><\/tr>
    Jun 1, 2021<\/td>Amended Patent Law takes effect<\/td>Confirmed<\/td>[6]<\/a><\/td><\/tr>
    Jul 4, 2021<\/td>Patent linkage implementing measures in force<\/td>Confirmed<\/td>[7]<\/a><\/td><\/tr>
    Aug 5, 2022<\/td>Supreme People’s Court decides Chugai v. Haihe<\/td>Confirmed<\/td>[23]<\/a><\/td><\/tr>
    May 2025<\/td>Pfizer and 3SBio license SSGJ-707<\/td>Confirmed<\/td>[14]<\/a><\/td><\/tr>
    Jul 28, 2025<\/td>GSK and Hengrui agreements<\/td>Confirmed<\/td>[15]<\/a><\/td><\/tr>
    Sep 9, 2025<\/td>NMPA announces 30-working-day IND pathway<\/td>Confirmed<\/td>[20]<\/a><\/td><\/tr>
    Sep 10, 2025<\/td>NYT publishes draft US order on China licensing<\/td>Draft reported; no signed order in source<\/td>[13]<\/a><\/td><\/tr>
    Dec 7, 2025<\/td>2025 NRDL and first commercial insurance innovative drug list released<\/td>Confirmed<\/td>[21]<\/a><\/td><\/tr>
    Dec 18, 2025<\/td>BIOSECURE Act signed in FY2026 NDAA<\/td>Confirmed<\/td>[9]<\/a><\/td><\/tr>
    Jan 29, 2026<\/td>FDA accepts Summit’s ivonescimab BLA<\/td>Confirmed<\/td>[18]<\/a><\/td><\/tr>
    Jan 30, 2026<\/td>AstraZeneca and CSPC agreement<\/td>Confirmed<\/td>[16]<\/a><\/td><\/tr>
    May 15, 2026<\/td>China data protection measures take effect<\/td>Confirmed<\/td>[3]<\/a><\/td><\/tr>
    Jun 8, 2026<\/td>DoD 1260H list update names WuXi AppTec<\/td>Confirmed<\/td>[10]<\/a> [11]<\/a><\/td><\/tr>
    Sep 2, 2026<\/td>FDA leaders publish “Good Clinical Practices Are Not Optional”<\/td>Confirmed<\/td>[12]<\/a><\/td><\/tr>
    Nov 14, 2026<\/td>PDUFA date for ivonescimab BLA<\/td>Announced future date<\/td>[18]<\/a><\/td><\/tr>
    By Dec 18, 2026<\/td>OMB list of biotechnology companies of concern due<\/td>Statutory deadline<\/td>[9]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Opportunities: How Big Was China’s 2025 Licensing Year?<\/strong><\/h2>\n\n\n\n

    How much did China out-licensing grow in 2025?<\/strong><\/h3>\n\n\n\n

    Total deal value grew 161.5% in one year. Deal count grew 67.0%. Both figures are our calculations from PharmCube data. [1]<\/a><\/p>\n\n\n\n

    \n

    Total annual transaction value “soared from USD 51.9 billion to USD 135.7 billion” between 2024 and 2025, with upfront payments of USD 7.0 billion. (Juan Valencia S., PharmCube, writing in DIA Global Forum, March 2026) [1]<\/a><\/p>\n<\/blockquote>\n\n\n\n

    Metric<\/th>2024<\/th>2025<\/th>Change (analysis)<\/th><\/tr><\/thead>
    Total deal value<\/td>$51.9 billion<\/td>$135.7 billion<\/td>+161.5%<\/td><\/tr>
    Number of deals<\/td>94<\/td>157<\/td>+67.0%<\/td><\/tr>
    Average headline value per deal<\/td>about $552 million<\/td>about $864 million<\/td>+56.5%<\/td><\/tr>
    Upfront payments<\/td>not stated in source<\/td>$7.0 billion<\/td>5.2% of 2025 value<\/td><\/tr>
    Average upfront per deal<\/td>not stated in source<\/td>about $44.6 million<\/td>not applicable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Source for inputs: [1]<\/a>. The same source reports nine NewCo deals in 2025. It also lists two milestone payments triggered during 2025 of $300 million (July) and $250 million (November). [1]<\/a><\/p>\n\n\n\n

    What does IQVIA report about China-linked deals?<\/strong><\/h4>\n\n\n\n

    IQVIA’s Global R&D Trends 2026 report, dated March 25, 2026, says deals between China-headquartered companies and international companies reached an all-time high. [22]<\/a> The same page says trial starts from China-headquartered sponsors declined, while trial starts from US-headquartered sponsors increased. [22]<\/a> It also reports that 30 novel active substances launched only in China. [22]<\/a><\/p>\n\n\n\n

    These findings point in different directions. Deal activity rose while trial starts by Chinese sponsors fell. The IQVIA page we reviewed does not explain the gap.<\/p>\n\n\n\n

    Which deals set the terms?<\/strong><\/h3>\n\n\n\n

    Pfizer and 3SBio: SSGJ-707, $1.25 billion upfront<\/strong><\/h4>\n\n\n\n

    Pfizer licensed SSGJ-707, a bispecific antibody that targets PD-1 and VEGF. Pfizer paid $1.25 billion upfront. 3SBio can earn up to $4.8 billion in development, regulatory and commercial milestones. 3SBio also receives tiered double-digit royalties on sales if the drug is approved. [14]<\/a><\/p>\n\n\n\n

    Pfizer also agreed to make a $100 million equity investment in 3SBio at closing. [14]<\/a> The license is exclusive and global, excluding China. Pfizer holds an option for commercialization rights in China. [14]<\/a><\/p>\n\n\n\n

    GSK and Hengrui: HRS-9821 plus up to 11 more programmes<\/strong><\/h4>\n\n\n\n

    On July 28, 2025, GSK announced agreements with Hengrui Pharma for up to 12 programmes. GSK pays $500 million upfront. The potential milestone total is “approximately $12 billion if all programmes are optioned and all milestones are achieved.” [15]<\/a><\/p>\n\n\n\n

    The lead programme is HRS-9821, a PDE3\/4 inhibitor in clinical development as add-on maintenance treatment for COPD. GSK holds a worldwide license excluding mainland China, Hong Kong, Macau and Taiwan. [15]<\/a> Hengrui Pharma’s Frank Jiang, Executive Vice President and Chief Strategy Officer, said “GSK brings additional R&D expertise, a robust global clinical network, and broad regulatory capabilities.” [15]<\/a><\/p>\n\n\n\n

    AstraZeneca and CSPC: SYH2082 plus seven programmes<\/strong><\/h4>\n\n\n\n

    On January 30, 2026, AstraZeneca announced an agreement with CSPC Pharmaceuticals for eight programmes. The release states $1.2 billion upfront and up to $3.5 billion in development and regulatory milestones. It also names sales milestones and tiered royalties but does not quantify them. [16]<\/a><\/p>\n\n\n\n

    The lead asset, SYH2082, is a long-acting GLP1R\/GIPR agonist moving into Phase I. AstraZeneca gets exclusive global rights outside China. CSPC keeps China, Taiwan, Hong Kong and Macau, and AstraZeneca may opt in to co-commercialise after approval there. [16]<\/a><\/p>\n\n\n\n

    AstraZeneca’s release does not state a total deal value. A trade report puts the headline total near $18.5 billion. [30]<\/a> Upfront plus the stated development and regulatory milestones equals $4.7 billion. That sum is our calculation.<\/p>\n\n\n\n

    Upfront vs. headline value: how much cash is guaranteed?<\/strong><\/h3>\n\n\n\n

    Upfront cash ranged from 4.0% to 29.5% of headline value across six deals in our sample. The simple average was 17.2%. Both figures are analysis. The bases differ by deal, so read the table as a range and not as a ranking of deal quality.<\/p>\n\n\n\n

    Deal<\/th>Year<\/th>Upfront<\/th>Headline basis<\/th>Upfront share<\/th>Source<\/th><\/tr><\/thead>
    GSK and Hengrui<\/td>2025<\/td>$0.5 billion<\/td>$12.5 billion (upfront plus about $12 billion milestones if all programmes optioned)<\/td>4.0%<\/td>[15]<\/a><\/td><\/tr>
    Summit and Akeso<\/td>2022<\/td>$0.5 billion<\/td>$5.0 billion<\/td>10.0%<\/td>[17]<\/a><\/td><\/tr>
    BMS and BioNTech (BNT327)<\/td>2025<\/td>$1.5 billion<\/td>$11.1 billion<\/td>13.5%<\/td>[17]<\/a> [30]<\/a><\/td><\/tr>
    Pfizer and 3SBio<\/td>2025<\/td>$1.25 billion<\/td>$6.05 billion (upfront plus $4.8 billion milestones; excludes $100 million equity)<\/td>20.7%<\/td>[14]<\/a><\/td><\/tr>
    AstraZeneca and CSPC<\/td>2026<\/td>$1.2 billion<\/td>$4.7 billion (upfront plus development and regulatory milestones only)<\/td>25.5%<\/td>[16]<\/a><\/td><\/tr>
    Novartis and BeiGene<\/td>2021<\/td>$0.65 billion<\/td>about $2.2 billion in named payments<\/td>29.5%<\/td>[17]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    DrugPatentWatch reports that the BMS and BioNTech deal also carries $2 billion in non-contingent anniversary payments through 2028. It puts the guaranteed share at $3.5 billion, or 31.5% of the $11.1 billion headline. [17]<\/a><\/p>\n\n\n\n

    Where do deal data sources disagree?<\/strong><\/h3>\n\n\n\n

    Trackers report different totals for China out-licensing. The table lists each figure with its source, so a reader can pick one and cite it correctly.<\/p>\n\n\n\n

    Statistic<\/th>Value<\/th>Reported by<\/th>Source<\/th><\/tr><\/thead>
    2025 total deal value<\/td>$135.7 billion<\/td>PharmCube, via DIA Global Forum<\/td>[1]<\/a><\/td><\/tr>
    2025 value<\/td>$138.8 billion of $275.1 billion<\/td>SS&C Intralinks, via DrugPatentWatch<\/td>[17]<\/a><\/td><\/tr>
    Share of H1 2025 licensing<\/td>32%<\/td>Jefferies\/BioWorld, via DrugPatentWatch<\/td>[17]<\/a><\/td><\/tr>
    Share of large pharma licensing deals from Chinese partners<\/td>38%<\/td>PharmExec (June 9, 2026), via DrugPatentWatch<\/td>[17]<\/a><\/td><\/tr>
    Average upfront, China-sourced deal<\/td>$52 million (2022) to $172 million (early 2026)<\/td>PharmExec, via DrugPatentWatch<\/td>[17]<\/a><\/td><\/tr>
    Q1 2026 cross-border value<\/td>about $60 billion, up about 73%<\/td>Trade report citing SCMP; we could not verify against a primary source<\/td>[30]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    The average upfront of $172 million does not match our $44.6 million figure for 2025. The two figures use different datasets and different deal definitions. We did not reconcile them.<\/p>\n\n\n\n

    Why Do Licensing Deals Exclude China? The Territory Architecture<\/strong><\/h2>\n\n\n\n

    In the four deals we checked, the Western licensee did not receive China. Pfizer has an option, and AstraZeneca has an opt-in right. [14]<\/a> [16]<\/a><\/p>\n\n\n\n

    Deal<\/th>Licensee territory<\/th>China position<\/th>Source<\/th><\/tr><\/thead>
    Pfizer and 3SBio<\/td>Global, excluding China<\/td>Pfizer holds an option for China commercialization rights<\/td>[14]<\/a><\/td><\/tr>
    GSK and Hengrui<\/td>Worldwide, excluding mainland China, Hong Kong, Macau and Taiwan<\/td>Excluded from GSK license<\/td>[15]<\/a><\/td><\/tr>
    AstraZeneca and CSPC<\/td>Global, excluding China<\/td>CSPC keeps China, Taiwan, Hong Kong and Macau; AstraZeneca may opt in to co-commercialise after approval<\/td>[16]<\/a><\/td><\/tr>
    Summit and Akeso<\/td>North America, South America, Europe, Middle East, Africa and Japan<\/td>China not in Summit’s listed license territories<\/td>[18]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Analysis: A territory split means two companies hold rights to one molecule. Each company runs its own regulatory filings, pricing talks and launch plan in its territory. For IP counsel, each deal creates at least two patent and exclusivity positions to track. The sources do not describe how the parties divide enforcement duties, so we do not assume a pattern.<\/p>\n\n\n\n

    Case study: ivonescimab, Summit and Akeso<\/strong><\/h3>\n\n\n\n

    Akeso engineered ivonescimab. Summit holds rights in its license territories, where the drug is called SMT112. Outside those territories, Akeso uses the name AK112. [18]<\/a><\/p>\n\n\n\n

    What is the FDA reviewing, and when is the decision?<\/strong><\/h4>\n\n\n\n

    On January 29, 2026, Summit announced FDA acceptance of a Biologics License Application. The application covers ivonescimab with platinum-doublet chemotherapy for adults with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC whose disease progressed after a third-generation EGFR TKI. The PDUFA target action date is November 14, 2026. [18]<\/a> The application rests on HARMONi, which Summit describes as a Phase III global study. [18]<\/a><\/p>\n\n\n\n

    The release does not give the share of HARMONi patients enrolled in China, so we cannot say how FDA’s data-site scrutiny, covered below, applies to this file.<\/p>\n\n\n\n

    China Patent Term Extension: How Many Extra Years Can a Drug Patent Get?<\/strong><\/h2>\n\n\n\n

    A new-drug patent in China can receive up to five extra years. Total patent life after the drug launches cannot exceed 14 years. [5]<\/a><\/p>\n\n\n\n

    What does Article 42 of the Patent Law say?<\/strong><\/h3>\n\n\n\n

    Under Article 42(3), CNIPA “may grant an extension of the term of a patent related to a new drug” at the patentee’s request. The maximum extension “shall not exceed five years,” and the total effective term after launch “shall not exceed 14 years.” [5]<\/a> The amended law took effect on June 1, 2021. [5]<\/a><\/p>\n\n\n\n

    How does China’s rule compare with US patent term extension?<\/strong><\/h3>\n\n\n\n

    The caps are the same size. In the US, 35 U.S.C. 156 limits extension to five years and reduces it so that total patent life after approval does not exceed 14 years. [29]<\/a> The data protection periods differ. China gives six years to innovative drugs. [3]<\/a> FDA lists five years of new chemical entity exclusivity. [28]<\/a><\/p>\n\n\n\n

    Rule<\/th>China<\/th>United States<\/th>Source<\/th><\/tr><\/thead>
    Maximum patent term extension<\/td>5 years<\/td>5 years<\/td>[5]<\/a> [29]<\/a><\/td><\/tr>
    Cap on patent life after approval<\/td>14 years<\/td>14 years<\/td>[5]<\/a> [29]<\/a><\/td><\/tr>
    Data protection for a new drug<\/td>6 years (innovative drugs)<\/td>5 years (new chemical entity exclusivity)<\/td>[3]<\/a> [28]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Does China compensate for patent office delay?<\/strong><\/h3>\n\n\n\n

    Yes, with limits. Under Article 42(2), CNIPA grants an extension for unreasonable examination delay. It applies only when the patent is granted more than four years after filing, or more than three years after the request for substantive examination. CNIPA grants no extension for delays that the applicant caused. [5]<\/a><\/p>\n\n\n\n

    Illustrative arithmetic: the 14-year cap in practice<\/strong><\/h4>\n\n\n\n

    This is hypothetical arithmetic from the Article 42(3) caps. It does not describe a real drug. The upper bound on extension is the lesser of five years and (14 minus the years left at launch). [5]<\/a> The sources we reviewed do not list the other conditions that set the actual extension.<\/p>\n\n\n\n

    Years left at launch<\/th>Upper bound on extension<\/th>Maximum life after launch<\/th><\/tr><\/thead>
    6<\/td>5 years<\/td>11 years<\/td><\/tr>
    9<\/td>5 years<\/td>14 years<\/td><\/tr>
    11<\/td>3 years<\/td>14 years<\/td><\/tr>
    13<\/td>1 year<\/td>14 years<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    China Regulatory Data Protection 2026: Six, Four and Three Years<\/strong><\/h2>\n\n\n\n

    China’s NMPA issued final regulatory data protection measures on May 15, 2026. They took effect the same day. [3]<\/a> [4]<\/a> The maximum term is six years from marketing approval in China. [4]<\/a><\/p>\n\n\n\n

    Which drugs get six, four or three years?<\/strong><\/h3>\n\n\n\n
    Category<\/th>Protection<\/th>Notes<\/th>Source<\/th><\/tr><\/thead>
    Innovative drugs (Category 1)<\/td>6 years<\/td>Covers CMC and clinical data on safety, efficacy and quality<\/td>[3]<\/a> [4]<\/a><\/td><\/tr>
    Overseas-marketed originator drugs first launched in China<\/td>6 years<\/td>Category 5.1 chemical drugs; Category 3.1 biologics<\/td>[3]<\/a><\/td><\/tr>
    Improved drugs<\/td>4 years<\/td>New clinical data showing clear clinical advantage<\/td>[3]<\/a> [4]<\/a><\/td><\/tr>
    New indication, first filed globally in China, full data package<\/td>6 years<\/td>Later additional indications may receive 4 years<\/td>[3]<\/a> [4]<\/a><\/td><\/tr>
    First approved generics in listed categories<\/td>3 years<\/td>Limited to necessary clinical data<\/td>[3]<\/a> [4]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Do biosimilars get data protection in China?<\/strong><\/h4>\n\n\n\n

    The two law-firm sources differ. Ropes & Gray states that follow-on generics, follow-on vaccines, biosimilars and other biological products outside the listed categories get no protection. [4]<\/a> Jones Day lists a three-year period for first-to-file products in Category 3.2 for biologics. [3]<\/a> The category definitions in the NMPA text decide which reading applies to a given product. Check that text before you rely on either summary.<\/p>\n\n\n\n

    What data does the regime protect, and what does it block?<\/strong><\/h3>\n\n\n\n

    Protected data includes pharmacological, nonclinical and clinical trial data that show safety, efficacy and quality. Bioavailability, bioequivalence and vaccine immunogenicity data are excluded. [3]<\/a> During the protection period, NMPA will not approve an improved or generic drug that relies on the protected data without the holder’s consent. [3]<\/a> A follower that generates its own data is unaffected. [3]<\/a><\/p>\n\n\n\n

    Jones Day reports that the measures give imported and domestically made drugs equal protection. [3]<\/a><\/p>\n\n\n\n

    How do you apply, and what was the transition deadline?<\/strong><\/h3>\n\n\n\n

    An applicant must request protection when it files the marketing authorization application. [3]<\/a> For drugs approved or under review on May 15, 2026, holders could file with the Center for Drug Evaluation within 15 working days. Jones Day gives June 5, 2026 as the latest date. [3]<\/a> Ropes & Gray states that a pending applicant who did not submit in time is treated as having waived protection. [4]<\/a><\/p>\n\n\n\n

    How do data protection and patent term extension stack?<\/strong><\/h3>\n\n\n\n

    Analysis: The two rules run on different clocks and block different things. Data protection runs up to six years from approval and stops NMPA from approving followers that rely on the originator’s data. [4]<\/a> Patent term extension can carry patent life to a maximum of 14 years after launch. [5]<\/a> After year six, only patents and the linkage process restrain a follower that files its own bridging evidence or relies on non-protected data. The sources we reviewed do not test this interaction in a decided case.<\/p>\n\n\n\n

    China Patent Linkage: How Does It Work, and Who Wins?<\/strong><\/h2>\n\n\n\n

    Article 76 of the amended Patent Law gives a patent owner a cause of action before a generic reaches the market. Before the amendment, a patent owner could not sue until the generic launched. [6]<\/a><\/p>\n\n\n\n

    What are the four patent certification categories?<\/strong><\/h3>\n\n\n\n

    A generic applicant files one of four certifications for each listed patent. [7]<\/a><\/p>\n\n\n\n